Editorial: Sulfonylureas differ in effects on ischemic preconditioning - Is it time to retire glyburide?

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 2, 2003, Pages 528-530

  Riddle, Matthew C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR RISK; DRUG EFFECT; EDITORIAL; HEART INFARCTION PREVENTION; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING; SULFONYLUREA COMPOUNDS;

EID: 0037326224     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021971     Document Type: Editorial

References (25)

1. Meinert CL, Knatterud GL, Prout TE, Klimt CR 1970 A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(Suppl 2):789-830
2. Feinglos MN, Bethel MA 1999 Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 138:S346-S352
3. United Kingdom Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
4. Jollis JG, Simpson Jr RJ, Cascio WE, Chowdhury MK, Crouse JR, Smith Jr SC 1999 Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 138:S376-S380
5. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes Jr DR 1999 Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124
6. Deutsch E, Berger M, Kussmaul WG, Hirschfeld Jr JW, Herrmann HC, Laskey WK 1990 Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolid features. Circulation 82:2044-2051
7. Kloner RA, Yellon D 1994 Does ischemic preconditioning occur in patients? J Am Coll Cardiol 24:1133-1142
8. + channel-opening drugs. Am J Physiol 269:C525-C545
9. ATP channels in preconditioning. Circ Res 87:845-855
10. ATP channels. Physiol Rev 78:227-245
11. Lazdunski M 1996 Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 28:488-495
12. Ashcroft FM 1996 Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 28:456-463
13. Kramer W, Muller G, Geisen K 1996 Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at β-cells. Horm Metab Res 28:464-468
14. Geisen K, Vagh A, Krause E, Papp JG 1996 Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 28:496-507
15. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM 2001 Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 103:3111-3116
16. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH 1997 Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96:29-32
17. + channel blocker. Circulation 90:700-705
18. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W 1999 Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439-446
19. Scognamiglio R, Avogara A, Vigili de Kreutzenberg S, Negut C, Palisi M, Bagolin E, Tiengo A 2002 Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51:808-812
20. Lee T-M, Chou T-F 2003 Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 88:531-537
21. Tosaki A, Szerdahelyi P, Engelman RM, Das DK 1993 Potassium channel openers and blockers: do they possess proarrthymic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 267:1355-1362
22. Holstein A, Plaschke A, Egberts E-H 2001 Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467-473
23. McNulty PH, Pfau S, Deckelbaum LI 2000 Effect of plasma insulin level on myocardial blood flow and its mechanism of action. Am J Cardiol 85:161-165
24. Malmberg K for the DIGAMI Study Group 1997 Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1552
25. Malmberg K, McGuire DK 1999 Diabetes and acute myocardial infarction: the role of insulin therapy. Am Heart J 138:S381-S386